

Lorena Rami Gonzalez

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5942126/lorena-rami-gonzalez-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

2,980
citations

23
h-index

54
g-index

71
ext. papers

3,736
ext. citations

4.3
avg, IF

4.27
L-index

#	Paper	IF	Citations
61	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 844-52	1.2	1219
60	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015 , 48 Suppl 1, S63-86	4.3	253
59	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017 , 13, 296-311	1.2	245
58	Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 901-8	4.3	79
57	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. <i>Journal of Hepatology</i> , 2011 , 55, 564-573	13.4	78
56	The Subjective Cognitive Decline Questionnaire (SCD-Q): a validation study. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 453-66	4.3	76
55	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1259-1272	1.2	67
54	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 546-560	7.6	66
53	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 297-304	2.5	63
52	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels. <i>Neurobiology of Aging</i> , 2014 , 35, 2671-2680	5.6	56
51	Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. <i>Journal of Alzheimer's Disease</i> , 2011 , 23, 319-26	4.3	56
50	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. <i>Neurobiology of Aging</i> , 2016 , 38, 47-55	5.6	42
49	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2015 , 48 Suppl 1, S87-98	4.3	39
48	Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 31, 517-26	4.3	39
47	Normative data for the Boston Naming Test and the Pyramids and Palm Trees Test in the elderly Spanish population. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2008 , 30, 1-6	2.1	34
46	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 127-34	3.9	33
45	The β genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 6, 50-59	5.2	29

44	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017 , 54, 6647-6654	6.2	29
43	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015 , 48 Suppl 1, S171-91	4.3	29
42	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , 2020 , 16, 262-272	1.2	29
41	Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 919-27	4.3	27
40	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019 , 15, 817-827	1.2	26
39	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 33	9	22
38	Cognitive status of psychiatric patients under maintenance electroconvulsive therapy: a one-year longitudinal study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004 , 16, 465-71	2.7	21
37	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid- β and Tau. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 1575-1587	4.3	20
36	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 8	9	19
35	Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 689-703	4.3	19
34	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019 , 15, 185-193	1.2	19
33	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. <i>NeuroImage: Clinical</i> , 2019 , 23, 101927	5.3	18
32	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019 , 22, 101777	5.3	17
31	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , 2019 , 23, 101801	5.3	17
30	Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. <i>NeuroImage: Clinical</i> , 2018 , 19, 190-201	5.3	15
29	The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1067-1077	4.3	15
28	Voxel based morphometry features and follow-up of amnesic patients at high risk for Alzheimer's disease conversion. <i>International Journal of Geriatric Psychiatry</i> , 2009 , 24, 875-84	3.9	15
27	Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 855-870	4.3	12

26	Cognitive functions after only one ECT session: a controlled study. <i>Psychiatry Research</i> , 2008 , 158, 389-94.9	11
25	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016 , 53, 5902-5911	6.2 9
24	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2 9
23	Subtle visuomotor difficulties in preclinical Alzheimer's disease. <i>Journal of Neuropsychology</i> , 2017 , 11, 56-73	2.6 8
22	Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 726-736	5.2 8
21	Initial phase of adaptation of Memory Alteration Test (M@T) in a Portuguese sample. <i>Archives of Gerontology and Geriatrics</i> , 2015 , 61, 103-8	4 7
20	Wishes and preferences for an online lifestyle program for brain health-A mixed methods study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 141-149	6 7
19	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2019 , 70, 211-225	4.3 6
18	Physical activity is associated with better global cognition and frontal function in overweight/obese older adults with metabolic syndrome. <i>European Review of Aging and Physical Activity</i> , 2019 , 16, 23	6.5 6
17	Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid- β Levels. <i>Journal of Alzheimer's Disease</i> , 2019 , 72, 1287-1302	4.3 5
16	Accelerated long-term forgetting over three months in asymptomatic APOE e4 carriers. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 477-484	5.3 5
15	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid- β positivity. <i>Cortex</i> , 2019 , 121, 117-124	3.8 3
14	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid- β positivity. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 1037-1049	3.9 2
13	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020 , 16, e036954	1.2 1
12	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 1413-1422	4.3 1
11	Distinct neuropsychological presentation and progression between early- and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e036809	1.2
10	Accelerated long-term forgetting over six months in cognitively normal APOE e4 carriers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041928	1.2
9	P2-335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples 2016 , 12, P770-P771	

- 8 IC-P-048: Longitudinal changes in gray matter volume in preclinical Alzheimer's disease **2015**, 11, P38-P39
- 7 [P2B55]: CSF STREM2, BUT NOT YKL-40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE **2017**, 13, P758-P758
- 6 [P3B66]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P1195-P1196
- 5 [P4B14]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE **2017**, 13, P1348-P1349
- 4 [TD-P-020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P166-P167
- 3 IC-02-05: Cerebrospinal Fluid Strem2 Levels are Associated with Gray Matter Volume Increases and Reduced Diffusivity in Early Alzheimer's Disease **2016**, 12, P8-P8
- 2 IC-02-05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERLY **2019**, 15, P4-P4
- 1 P2-262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM **2018**, 14, P777-P777